News | April 05, 2026
Senores makes bold US push with new federal-focused JV
Company leadership is framing the move as transformational.
Company leadership is framing the move as transformational.
The company has highlighted setbacks in Phase II studies while outlining fresh regulatory and late-stage development plans for Fibromun and Nidlegy
Parliament clears reform bill replacing jail terms for procedural lapses with graded monetary penalties across key health laws
The company spotlights micronutrient’s role in immunity, skin and bone health through digital and radio outreach on National Vitamin C Day
Industry, policymakers focus on AI-led regulatory harmonisation, FTAs, MSME support and market expansion as exports touch $28.29 billion till February FY26
The SirPAD trial marks a significant milestone in vascular intervention, positioning MagicTouch PTA as a promising future alternative for PAD treatment
Its a major breakthrough for women’s ovarian cancer care in Europe
The trial, dubbed MALBEC, marks the first in a broader late-phase development push for MK-8748, with a second NVAMD study expected to begin later this year
DBT-BIRAC, BioE3 and the Rs 10,000-crore Biopharma SHAKTI scheme aim to accelerate innovation, biomanufacturing and exports
Ac-225, an alpha-emitting radionuclide, can be paired with molecules designed to selectively target cancer cells.
Subscribe To Our Newsletter & Stay Updated
